Prognosis Factors in Chronic Lymphocytic Leukemia.

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Chronic lymphocytic leukemia (CLL) remains a prevalent hematologic malignancy.
• Identifying curative strategies and optimizing treatment timing are critical research objectives.
• Prognostic factors significantly influence CLL progression and treatment response.

Purpose of the Study:

• To review the impact of prognostic factors on Chronic lymphocytic leukemia (CLL) evolution.
• To discuss the efficacy of combined therapeutic regimens adapted to prognostic factors.
• To highlight the significance of minimal residual disease (MRD) as a prognostic marker.

Main Methods:

• Analysis of classic diagnostic elements and newly identified prognostic factors in CLL.
• Review of clinical trials evaluating combined therapeutic regimens.
• Assessment of minimal residual disease (MRD) as a prognostic indicator.

Main Results:

• CD38, ZAP 70, IgHV gene mutational status, and cytogenetic changes negatively impact CLL.
• Combined therapeutic regimens, adapted to prognostic factors, improve durable complete remission rates.
• Absence of minimal residual disease (MRD) post-treatment is a strong positive prognostic factor.

Conclusions:

• CLL management requires consideration of multiple prognostic factors.
• Targeted therapeutic strategies are essential for improving patient outcomes.
• Minimal residual disease (MRD) assessment is crucial for predicting treatment success and long-term prognosis.